Related Experiment Video

Updated: Sep 29, 2026

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

Antiangiogenic effects of somatostatin analogues

N García de la Torre1, J A H Wass, H E Turner

  • 1Department of Endocrinology, Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE, UK.

Clinical Endocrinology
|October 2, 2002
PubMed

Insights

Somatostatin analogues show potential for inhibiting tumor growth and retinal neovascularization by targeting angiogenesis. Further research is needed to confirm their effectiveness and explore analogues with varied receptor affinities for enhanced cancer therapy.

Area of Science:

  • Oncology
  • Vascular Biology
  • Endocrinology

Background:

  • Angiogenesis inhibition is a key strategy for antineoplastic therapy and treating retinal neovascularization.
  • Somatostatin receptors are present on tumor cells and vascular endothelium, prompting investigation into somatostatin analogues' effects.
  • Existing data suggest somatostatin analogues may inhibit angiogenesis directly and indirectly by affecting growth factors and monocyte chemotaxis.

Purpose of the Study:

  • To investigate the antiproliferative and antiangiogenic effects of somatostatin analogues.
  • To evaluate the potential of somatostatin analogues in cancer and retinal neovascularization therapies.
  • To explore the role of somatostatin receptor subtypes in mediating these effects.

Main Methods:

  • In vitro and in vivo studies were conducted.
  • Analysis of somatostatin analogues' effects on endothelial cells and growth factor secretion (IGF-I, VEGF).
  • Investigation of somatostatin receptor subtype affinities (sst2, sst5, sst3).

Main Results:

  • Somatostatin analogues show potential antiproliferative and antiangiogenic effects.
  • Mechanisms include direct action on endothelial somatostatin receptors and indirect inhibition of growth factors.
  • Some studies question the beneficial effects on neovascularization, indicating a need for more research.

Conclusions:

  • Somatostatin analogues may inhibit angiogenesis, offering a potential therapeutic avenue.
  • Further research is required to establish their definitive role in antiangiogenic therapy.
  • Investigating analogues with diverse somatostatin receptor affinities could broaden therapeutic options for tumors.

More Related Videos

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...